IDEXX Laboratories, Inc. $IDXX Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.2% during the 1st quarter, Holdings Channel.com reports. The fund owned 122,654 shares of the company’s stock after selling 2,748 shares during the period. California State Teachers Retirement System’s holdings in IDEXX Laboratories were worth $68,918,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV boosted its holdings in shares of IDEXX Laboratories by 76.9% in the 4th quarter. KBC Group NV now owns 309,380 shares of the company’s stock valued at $209,305,000 after buying an additional 134,493 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $3,666,459,000. Sumitomo Mitsui Trust Group Inc. grew its position in shares of IDEXX Laboratories by 4.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 209,106 shares of the company’s stock valued at $141,466,000 after acquiring an additional 8,626 shares during the period. NewEdge Wealth LLC increased its stake in shares of IDEXX Laboratories by 122.3% during the 4th quarter. NewEdge Wealth LLC now owns 6,597 shares of the company’s stock worth $4,463,000 after purchasing an additional 3,629 shares during the last quarter. Finally, Fortem Financial Group LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $2,068,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent analyst reports. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group cut their price target on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating for the company in a report on Monday. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $749.00.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $558.80 on Friday. The firm has a 50-day moving average price of $557.37 and a two-hundred day moving average price of $590.62. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The company has a market capitalization of $44.08 billion, a P/E ratio of 41.15, a P/E/G ratio of 3.12 and a beta of 1.55. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the company posted $2.91 earnings per share. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.